BC Extra | Dec 22, 2018
Financial News

Gossamer Bio seeks $264.5 million IPO one year after launch

Gossamer Bio Inc. (San Diego, Calif.) plans to raise up to $264.5 million in an IPO on NASDAQ, according to a Dec. 21 SEC filing. The company was launched by ex-Receptos Inc. executives in January...
BC Innovations | Apr 2, 2015
Targets & Mechanisms

Breathing through bone drugs

Reversing or halting progressive airway damage is still the biggest challenge in COPD, but a study from Japan suggests a subclass of osteoporosis drugs could offer a new way to tackle the disease that takes...
BioCentury | Aug 18, 2014
Strategy

Breathing room

AstraZeneca plc 's acquisition of Almirall S.A. 's respiratory assets should buy the pharma time while its respiratory pipeline matures. The deal not only gives AstraZeneca a faster route to market in the COPD combination...
BC Week In Review | Oct 1, 2012
Company News

Pulmagen, Teijin deal

Pulmagen granted Teijin exclusive rights to develop and commercialize ADC3680 in Japan. Teijin plans to start Phase I testing of ADC3680 in Japan in April 2013 for asthma. The oral small molecule prostaglandin D2 (PGD2)...
BC Extra | Sep 27, 2012
Company News

Teijin receives Japanese rights to Pulmagen's asthma product

Pulmagen Therapeutics Ltd. (Slough, U.K.) granted Teijin Pharma Ltd. (Tokyo, Japan) exclusive rights in Japan to develop and commercialize asthma product ADC3680 . Teijin plans to start Phase I testing of ADC3680 in Japan in April...
BC Week In Review | Feb 8, 2010
Company News

Argenta Discovery, Galapagos deal

Galapagos acquired Argenta's contract research business for €16.5 million ($22.9 million) in cash. Galapagos said the deal will expand its existing drug discovery services. Argenta reported 2009 revenue of €14 million ($19.4 million). The contract...
BioCentury | Feb 8, 2010
Finance

Regulatory milestones

Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) gained $2.88 (10%) to $31.04 last week after FDA approved a BLA for Xiaflex collagenase clostridium histolyticum to treat Dupuytren's contracture, a condition that affects the joints in the hand. Auxilium...
BC Extra | Feb 3, 2010
Company News

Galapagos acquires Argenta service business

Galapagos N.V. (Euronext:GLPG; Pink:GLPYY) acquired the contract research business of Argenta Discovery Ltd. (Harlow, U.K.) for EUR 16.5 million ($22.9 million) in cash. Galapagos said the acquisition will expand its existing drug discovery services. Argenta...
Items per page:
1 - 8 of 8
BC Extra | Dec 22, 2018
Financial News

Gossamer Bio seeks $264.5 million IPO one year after launch

Gossamer Bio Inc. (San Diego, Calif.) plans to raise up to $264.5 million in an IPO on NASDAQ, according to a Dec. 21 SEC filing. The company was launched by ex-Receptos Inc. executives in January...
BC Innovations | Apr 2, 2015
Targets & Mechanisms

Breathing through bone drugs

Reversing or halting progressive airway damage is still the biggest challenge in COPD, but a study from Japan suggests a subclass of osteoporosis drugs could offer a new way to tackle the disease that takes...
BioCentury | Aug 18, 2014
Strategy

Breathing room

AstraZeneca plc 's acquisition of Almirall S.A. 's respiratory assets should buy the pharma time while its respiratory pipeline matures. The deal not only gives AstraZeneca a faster route to market in the COPD combination...
BC Week In Review | Oct 1, 2012
Company News

Pulmagen, Teijin deal

Pulmagen granted Teijin exclusive rights to develop and commercialize ADC3680 in Japan. Teijin plans to start Phase I testing of ADC3680 in Japan in April 2013 for asthma. The oral small molecule prostaglandin D2 (PGD2)...
BC Extra | Sep 27, 2012
Company News

Teijin receives Japanese rights to Pulmagen's asthma product

Pulmagen Therapeutics Ltd. (Slough, U.K.) granted Teijin Pharma Ltd. (Tokyo, Japan) exclusive rights in Japan to develop and commercialize asthma product ADC3680 . Teijin plans to start Phase I testing of ADC3680 in Japan in April...
BC Week In Review | Feb 8, 2010
Company News

Argenta Discovery, Galapagos deal

Galapagos acquired Argenta's contract research business for €16.5 million ($22.9 million) in cash. Galapagos said the deal will expand its existing drug discovery services. Argenta reported 2009 revenue of €14 million ($19.4 million). The contract...
BioCentury | Feb 8, 2010
Finance

Regulatory milestones

Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) gained $2.88 (10%) to $31.04 last week after FDA approved a BLA for Xiaflex collagenase clostridium histolyticum to treat Dupuytren's contracture, a condition that affects the joints in the hand. Auxilium...
BC Extra | Feb 3, 2010
Company News

Galapagos acquires Argenta service business

Galapagos N.V. (Euronext:GLPG; Pink:GLPYY) acquired the contract research business of Argenta Discovery Ltd. (Harlow, U.K.) for EUR 16.5 million ($22.9 million) in cash. Galapagos said the acquisition will expand its existing drug discovery services. Argenta...
Items per page:
1 - 8 of 8